Analysis of cell cycle-related proteins in mediastinal lymph nodes of patients with N2-NSCLC obtained by EBUS-TBNA: Relevance to chemotherapy response

Thorax

Volumn 63, Issue 7, 2008, Pages 642-647

  Mohamed, S ^a,b   Yasufuku, K ^a   Nakajima, T ^a   Hiroshima, K ^a   Kubo, R ^a   Iyoda, A ^a   Yoshida, S ^a   Suzuki, M ^a   Sekine, Y ^a   Shibuya, K ^a   Farouk, A ^b   Fujisawa, T ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Assiut University Faculty of Medicine   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; PLATINUM DERIVATIVE; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; BRONCHOSCOPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG RESPONSE; ENDOBRONCHIAL ULTRASONOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSBRONCHIAL ASPIRATION; UNIVARIATE ANALYSIS;

AGED; ANTINEOPLASTIC AGENTS; BIOPSY, FINE-NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MEDIASTINUM; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 47049091770     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2007.090324     Document Type: Article

References (33)

1. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-92.
2. Viktorsson K, De Petris L, Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 2005;331:868-80.
3. Yasufuku K, Chhajed PN, Sekine Y, et al. Endobronchial ultrasound using a new convex probe: a preliminary study on surgically resected specimens. Oncol Rep 2004;11:293-6.
4. Yasufuku K, Chiyo M, Sekine Y, et al. Real-time endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal and hilar lymph nodes. Chest 2004;126:122-8.
5. Yasufuku K, Chiyo M, Koh E, et al. Endobronchial ultrasound guided transbronchial needle aspiration for staging of lung cancer. Lung Cancer 2005;50:347-54.
6. Herth FJ, Eberhardt R, Vilmann P, et al. Real-time endobronchial ultrasound guided transbronchial needle aspiration for sampling mediastinal lymph nodes. Thorax 2006;61:795-8.
7. Yasufuku K, Nakajima T, Motoori K, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest 2006;130:710-8.
8. Nakajima T, Yasufuku K, Suzuki M, et al. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2007;132:597-602.
9. Harada T, Ogura S, Yamazaki K, et al. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci 2003;94:394-9.
10. Gautschi O, Hugli B, Ziegler A, et al. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2006;51:303-11.
11. Travis WD, Brambilla E, Müller-Hermelink HK, et al. World Health Organization Classification of Tumours. Pathology and genetics. Tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC Press, 2004:10.
12. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718-23.
13. Burke L, Flieder DB, Guinee DG, et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res 2005;11:232-41.
14. Mohamed S, Yasufuku K, Hiroshima K, et al. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer. Cancer 2007;109:2506-14.
15. Shiba M, Kohno H, Kakizawa K, et al. Ki-67 Immunostaining and other prognostic factors including tobacco smoking in patients with resected non-small cell lung carcinoma. Cancer 2000;89:1457-65.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
17. Cox DR, Snell EJ. Analysis of binary data. 2nd ed. London: Chapman and Hall, 1989.
18. Geradts J, Fong KM, Zimmerman PV, et al. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 1999;5:791-800.
19. Mangili F, Cigala C, Arrigoni G, et al. Cell loss and proliferation in non-small cell lung carcinoma: correlation with histological subtype. Eur J Histochem 1998;42:287-95.
20. Esposito V, Baldi A, Tonini G, et al. Analysis of cell cycle regulator proteins in non-small cell lung cancer. J Clin Pathol 2004;57:58-63.
21. Tominaga O, Hamelin R, Remvikos Y, et al. p53 from basic research to clinical applications. Crit Rev Oncog 1992;3:257-82.
22. El-Deiry. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003;22:7486-95.
23. de Vries A, Flores ER, Miranda B, et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA 2002;99:2948-53.
24. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
25. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335-46.
26. Tsai CM, Chang KT, Li L, et al. Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn J Cancer Res 2000;91:213-22.
27. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004;15:1194-203.
28. Okamoto A, Hussain SP, Hagiwara K, et al. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 1995;55:1448-51.
29. Schlegel U, Rosenfeld MR, Volkenandt M, et al. p53 gene mutations in primary lung tumors are conserved in brain metastases. J Neurooncol 1992;14:93-100.
30. Bepler G. Using translational research to tailor the use of chemotherapy in the treatment of NSCLC. Lung Cancer 2005; 50(Suppl 1):P13.
31. Goldstraw P. Selection of patients for surgery after induction chemotherapy for N2 non-small-cell lung cancer (editorial). J Clin Oncol 2006;24:3317-8.
32. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002;8:282-8.
33. Fujiwara T, Tanaka N, Kanazawa S, et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006;24:1689-99.